Investigational drug · Phase 2
HMBD-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: May 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "HMBD-001"
First trial start
2024
Feb 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HMBD-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Cervical Squamous Cell Carcinoma
- Advanced Cutaneous Squamous Cell Carcinoma
- Nasopharyngeal Cancinoma (NPC)
- Squamous Cell Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HMBD-001" as an intervention, largest first.
Hummingbird BioscienceIndustry
NCT05910827 · 398 participants (planned) · Start Feb 5, 2024 · Primary completion Dec 1, 2027
Drug: HMBD-001; Docetaxel and 1 more · For: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Esophageal Squamous Cell Carcinoma and 4 more
Sites: Sydney, Australia; Westmead, Australia; Brisbane, Australia · 20 sites in all
- A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid TumoursActive, not recruiting
Cancer Research UKAcademic, hospital or other
NCT05057013 · 81 participants (planned) · Start Nov 10, 2021 · Primary completion Nov 2025
Drug: HMBD-001; HMBD-001 and enzalutamide · For: Bladder Cancer; Triple Negative Breast Cancer; Castration-resistant Prostate Cancer and 11 more
Sites: London, United Kingdom; Manchester, United Kingdom; Newcastle, United Kingdom · 4 sites in all
- Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 MutationActive, not recruiting
Hummingbird BioscienceIndustry
NCT05919537 · 68 participants (planned) · Start Sep 6, 2023 · Primary completion Mar 1, 2031
Drug: HMBD-001; Docetaxel and 2 more · For: Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor and 1 more
Sites: Sydney, Australia; Brisbane, Australia; Adelaide, Australia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum.
Idowu OS, Craigen JL, Veal GJ, et al. · Bioanalysis 2022
Also in development for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- HLX07Phase 34 trials
Shanghai Henlius Biotech · Colon Cancer Adenocarcinoma, Squamous NSCLC, Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.